Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448088 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TDP1TSHRPGDCYP2C19 | |
| SCHEMBL6805671 | 0.83 | PGD (0.50) | TDP1TSHRPGDCYP2C19 | |
| SCHEMBL667280 | 0.83 | PGD (0.50) | TDP1TSHRPGDCYP2C19 | |
| SCHEMBL6803525 | 0.83 | PGD (0.50) | TDP1TSHRPGDCYP2C19 | |
| SCHEMBL5783087 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TDP1TSHRPGDCYP2C19 | |
| SCHEMBL15905917 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| SCHEMBL3224348 | 0.76 | CYP2C19 (0.58) | ALDH1A1TDP1PGDCYP2C19TRPA1 | |
| SCHEMBL12081424 | 0.76 | TSHR (0.43) | TSHRPGDCYP2C19 | |
| SCHEMBL2467277 | 0.76 | TSHR (0.43) | ALDH1A1TDP1TSHRPGDCYP2C19 | |
| SCHEMBL11210487 | 0.76 | ALDH1A1 (0.43) | ALDH1A1TDP1PGDCYP2C19TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674330-B | Preparation method of 34-Dimethyl apratoxin A/E | 复旦大学 | 2021-07-02 | — | — | CN | claimed |
| US-11718645-B2 | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718645-B2 | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| CN-106674330-B | Preparation method of 34-Dimethyl apratoxin A/E | 复旦大学 | 2021-07-02 | — | — | CN | disclosed |
| EP-3107919-B1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIV FLORIDA (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200317732-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-10-08 | — | — | US | disclosed |
| WO-2019157293-A1 | APRATOXIN ANALOGS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190241611-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-08-08 | — | — | US | disclosed |
| US-20170057996-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057996-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2017-03-02 | — | — | US | disclosed |
| EP-3107919-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | University of Florida Research Foundation (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015127161-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015127161-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-1412323-B1 | PROTECTED 3,5-DIHYDROXY-2,2-DIMETHYL-VALERONITRILES FOR THE SYNTHESIS OF EPOTHILONES AND DERIVATIVES AND METHOD FOR THE PRODUCTION AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2009-09-30 | — | — | EP | disclosed |
| US-6919456-B2 | Catalytic compositions and methods for asymmetric aldol reactions | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1409122-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-6610889-B2 | Using organometallic complex catalyst | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2003-08-26 | — | — | US | disclosed |
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002041984-A2 | CATALYTIC COMPOSITIONS AND METHODS FOR ASYMMETRIC ALDOL REACTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718645-B2 | Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment | NFATC1, MCL1, ICOS | ALDH1A1 2615/4885TDP1 3096/4885TSHR 540/4885 |
| US-20200317732-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | ALDH1A1 2615/4885TDP1 3096/4885TSHR 540/4885 |
| US-20170057996-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | ALDH1A1 2615/4885TDP1 3096/4885TSHR 540/4885 |
| US-20020147367-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | ALDH1A1 26/4885TDP1 2601/4885TSHR 4511/4885 |
| US-20190241611-A1 | MACROCYCLIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE, AND METHODS OF TREATMENT | NFATC1, MCL1, ICOS | ALDH1A1 2615/4885TDP1 3096/4885TSHR 540/4885 |
| US-20040019239-A1 | Catalytic compositions and methods for asymmetric aldol reactions | ADH1C, ADH5, ADH1A | ALDH1A1 26/4885TDP1 2601/4885TSHR 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.